Clinigen

CSM Parent, Inc. provides packaging, labelling, warehousing, and distribution services.

iQone Healthcare Holding (Suisse) SA is a specialty pharmaceutical company based in Versoix, Switzerland, focused on therapeutic areas including oncology/hematology, immunology (specifically rheumatology and gastroenterology), and bones and tissues. Founded in 1979, the company has established itself in the pharmaceutical sector and operates as a subsidiary of Clinigen Group Plc. iQone's commitment to addressing specific medical needs in these therapeutic areas highlights its role in advancing healthcare solutions.

CSM solves complex clinical trial supply problems for biotech and pharmaceutical companies such as limited drug supply, time constraints and mid-study changes. They offer a unique blend of traditional and innovative services that can significantly shorten timelines, reduce costs and improve outcomes for clinical studies.

International Medical Management Corp. provide medical supply consulting services to the Japanese health care community.

Quantum Pharma is a service-led, niche pharmaceutical developer, manufacturer and supplier to the retail pharmacy, pharmaceutical wholesaler and hospital markets. Quantum Pharma operates through two divisions incorporating seven business units across six sites in the UK and Europe, offering a portfolio of innovative and synergistic products and services.

Totect® is the first and only approved treatment by the United States Food and Drug Administration for anthracycline extravasation.

Link Healthcare Pty Ltd., established in 1997 and located in Warriewood, Australia, is a specialist pharmaceutical company that focuses on distributing and marketing medicines and medical devices across Asia, Africa, and Australasia. The company provides a range of services including pharmaceutical sales and marketing, regulatory compliance, medical affairs, pharmacovigilance, logistics, and pharmaceutical licensing. As of October 30, 2015, Link Healthcare operates as a subsidiary of Clinigen Group Plc, enhancing its reach and capabilities in delivering clinically important pharmaceuticals in the Australian market.

Around the world, patients with unmet medical needs are frequently driven to seek access to medicines outside the clinical trial and commercial setting. Idis is the leading expert in developing, implementing and managing global Managed Access Programs by which pharmaceutical and biotechnology companies and healthcare providers can respond to the needs of these patients. Idis has over 27 years experience of partnering with pharmaceutical and biotechnology companies to create regulatory-compliant, ethical access to medicines for healthcare professionals and their patients with unmet medical needs. Since 1987, Idis has developed and managed access to thousands of medicines from virtually every therapeutic category, impacting the lives of hundreds of thousands of patients. Around the world, a variety of terms are used to describe these programs including “expanded access”, “named patient”, “ATU”, “compassionate use”, and “early access”.

Clinigen CTS Limited supplies drugs and ancillaries for global trials.